Table 1.

Main characteristics of studies exploring the relationship between SIRT6 expression and tumor prognosis

Authors	Year	Region	Cancer type	Stage/ Grade	No. of Patients	Follow-up Time Median (range)	Detection Method	Outcomes	Location	NOS Score
Zhang [14]	2020	Korea	OS	I–IV	37	NR	IHC (CST)	OS, DFS	NR	8
Han [15]	2019	China	HCC	NR	120	60 M	IHC (Bioss)	OS, DFS	NR	7
Bae [16]	2018	Korea	OC	I–IV	104	82 M(1–209)	IHC (CST)	OS, DFS	Nu	8
Tian [10]	2018	China	CRC	I–IV	90	NR	IHC (CST)	OS	Nu	7
Li [17]	2018	China	CRC	I–IV	97	NR	IHC (Abcam)	OS	Nu	7
Zhu [18]	2018	China	NSCLC	I–IV	86	51 M	IHC (Abcam)	OS, DFS	Nu	6
Chen [4]	2017	China	NSCLC	I–III	122	44 M(1–60)	IHC (Abcam)	OS	Cy	7
Zhou [19]	2017	China	GC	I–IV	68	NR	IHC (CST)	OS, DFS	NR	6
Bai [11]	2016	China	NSCLC	I–IV	174	30 M(0–120)	IHC (Abcam)	OS	NR	5
Bae [20]	2016	Korea	BRC	I–IV	142	148.8 M(7.7–198.6)	IHC (Lifespan)	OS, DFS	Nu	7
Kugel [9]	2016	USA	PDAC	NR	120	33 M	IHC (NR)	OS	NR	9
Ran [21]	2016	China	HCC	I–III	53	NR	IHC (Novus)	OS	NR	8
Azuma [22]	2015	Japan	NSCLC	I–IV	98	NR	IHC (Abnova)	OS	Cy	7
Thirumurthi [23]	2014	China	BRC	NR	126	NR	IHC (CST)	OS	NR	8
Khongkow [24]	2013	China	BRC	I–III	118	NR	IHC (CST)	OS	Nu	8

NR not report, M month, IHC immunohistochemistry, OC ovarian carcinomas, CRC colon cancer, NSCLC non-small cell lung cancer, GC gastric cancer, PDAC pancreatic ductal adenocarcinoma, HCC hepatocellular carcinoma, BRC breast cancer, OS osteosarcoma, Nu nucleus, Cy cytoplasm